Icagen, Inc.
4222 Emperor Boulevard
Suite 350
Durham
North Carolina
27703
United States
Tel: 919-941-5206
Fax: 919-941-0813
Website: http://www.icagen.com/
Email: info@icagen.com
About Icagen, Inc.
Icagen, Inc. is a public biopharmaceutical company focused on the discovery, development and commercialization of novel, orally-administered, small-molecule drugs that modulate ion channel targets. Using our proprietary know-how and integrated scientific and drug development capabilities, we have identified multiple drug candidates. Our two most advanced programs are:
We are also conducting ongoing drug discovery programs focused on new therapeutics for pain and inflammatory disorders. In each of these programs, we have identified small-molecule compounds that have demonstrated activity on specific ion channels. When we tested these compounds in preclinical studies, they showed desired activities and profiles, validating these ion channels as potential therapeutic targets for the particular indication. In addition to our internal programs, we have established a collaboration with Pfizer Inc focused on three sodium channel targets for the treatment of pain and related disorders. We plan to generate revenue from any product candidates that we successfully develop either through direct sales, collaboration arrangements with leading pharmaceutical and biotechnology companies, or a combination of these approaches.
For further information, see www.icagen.com.
Last Updated: 05-19-2008
177 articles about Icagen, Inc.
-
Ligand Agrees to Acquire Core Assets, Partnered Programs and Ion Channel Technologies from Icagen
2/11/2020
Ligand Pharmaceuticals Incorporated announces the signing of an agreement whereby Ligand will acquire the core assets of Icagen, Inc.’s North Carolina operations, including partnered programs, proprietary ion channel screening and assay platforms, x-ray fluorescence capabilities, custom screening technologies and novel unpartnered preclinical-stage molecules for $15 million in cash.
-
Icagen enters into Collaboration to Develop and Commercialize Therapy for Neurological Diseases
12/5/2018
Collaboration includes the initial program utilizing Icagen's Drug Discovery Platform.
-
The Wilmington, Massachusetts-based contract research organization (CRO) Charles River Laboratories International extended its current collaboration with The Michael J. Fox Foundation for Parkinson’s Research (MJFF).
-
Icagen Receives Award from the Cystic Fibrosis Foundation to Discover Transformative Therapies to Treat Cystic Fibrosis
5/1/2018
Icagen, Inc., a company focused on the discovery of innovative therapies to treat patients with serious diseases, today announces an award from the Cystic Fibrosis Foundation.
-
Icagen, Inc. And Omdana Therapeutics Announce Collaboration To Pursue Therapies For Patients With Pulmonary Hypertension
6/20/2017
-
Icagen, Inc. Announces Collaboration With Bayer To Develop Novel XRpro Assays
3/28/2017
-
Icagen, Inc. Release: Company Announces Distribution Agreement With On Target For Advancing Early Drug Discovery In Japanese Market
1/10/2017
-
Icagen, Inc. Appoints Chris Mathes As Chief Commercial Officer
8/25/2016
-
Icagen, Inc. Acquires Nanion 's SyncroPatch384 High-Throughput Electrophysiology Platform
7/27/2016
-
Icagen, Inc. Acquisition Of Sanofi Arizona Research Facility Complete
7/19/2016
-
Icagen, Inc. Acquires Sanofi's Oro Valley, Arizona Research Facility
6/28/2016
-
Icagen, Inc. Issued U.S. Patent Covering Diagnostic And Discovery Applications Of Its Proprietary XRpro X-Ray Fluorescence Technology
5/16/2016
-
Aptuit LLC And Icagen, Inc. Agree To Strategic Alliance
2/22/2016
-
Icagen, Inc. To Showcase Ion Channel And Transporter Drug Discovery And Development Expertise At SLAS 2016
1/21/2016
-
AMRI And Icagen, Inc. Ink Collaboration Agreement
1/7/2016
-
Icagen, Inc. Launches Industry's Most Comprehensive Research Platform And Services For Sodium Channel Drug Discovery
10/1/2015
-
Icagen, Inc. Consolidates Operations At RTP Facility
10/1/2015
-
Icagen, Inc. Re-Launched Through XRpro Acquisition Of Pfizer Team And Technology For Ion Channel And Transporter Drug R&D
7/2/2015
-
EXCLUSIVE: XRpro's Revamped Icagen, Inc. May See Hiring, CEO Tells BioSpace
7/2/2015
-
Pfizer Inc. Completes Acquisition of Icagen, Inc.
10/28/2011